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Rezumat
Hiperlipidemia este un factor de risc bine stabilit pentru dezvoltarea bolilor cardiovasculare. Prin prevenirea 
distrugerii receptorilor LDL, nivelurile de LDL-C pot fi reduse cu 50% -60% peste cele obținute numai prin terapia 
cu statine. PCSK9 este o proprotein-сonvertază, care este implicată în degradarea receptorilor de lipoproteine cu 
densitate mică (LDL) în ficat. Mutațiile din gena PCSK9 determină hipercolesterolemie familială la un subgrup de 
pacienți prin reducerea numărului de receptori LDL de pe suprafața hepatocitelor. În schimb, alte mutații PCSK9 au 
ca rezultat concentrații neobișnuit de scăzute ale colesterolului LDL plasmatic și un risc redus de boală ateroscle-
rotică. Blocarea activității PCSK9 cu anticorpi monoclonali reduce degradarea receptorilor LDL și crește degajarea 
colesterolului LDL. Injectarea de anticorpi specifici PCSK9 suprimă concentrațiile de LDL-colesterol timp de câ-
teva săptămâni.
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Summary. PCSK9 inhibitors – a new drug of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease. By preventing LDL 
receptor destruction, LDL-C levels can be lowered 50%-60% above that achieved by statin therapy alone. PCSK9 
is a proprotein convertase which is involved in the degradation of low-density lipoprotein (LDL) receptors in the 
liver. Mutations in the PCSK9 gene cause familial hypercholesterolaemia in a subset of patients by reducing the 
number of LDL receptors on the surface of hepatocytes. Conversely, other PCSK9 mutations result in unusually 
low concentrations of plasma LDL cholesterol and a reduced risk of atherosclerotic disease. Blocking the activity of 
PCSK9 with monoclonal antibodies reduces the degradation of LDL receptors and increases the clearance of LDL 
cholesterol. An injection of PCSK9-specific antibody suppresses LDL-cholesterol concentrations for several weeks.
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Резюме. Ингибиторы PCSK9  -новая лекарственная липидная терапия
Гиперлипидемия – это установленный фактор риска развития сердечно-сосудистых заболеваний. Пу-
тем предотвращения разрушения LDL-рецептора уровни LDL-C могут быть снижены на 50-60% выше, чем 
при терапии статинами. PCSK9 представляет собой пропротеин-конвертазу, которая участвует в деградации 
рецепторов липопротеинов низкой плотности (LDL) в печени. Мутации в гене PCSK9 вызывают семей-
ную гиперхолестеринемию у пациентов, уменьшая количество рецепторов LDL на поверхности гепатоци-
тов. Напротив, другие мутации PCSK9 приводят к необычно низким концентрациям холестерина ЛПНП в 
плазме и снижению риска развития атеросклероза. Блокирование активности PCSK9 с моноклональными 
антителами снижает деградацию рецепторов LDL и увеличивает клиренс холестерина LDL. При инъекции 
PCSK9-специфического антитела подавляютcя   концентрации LDL-холестерина в течение нескольких не-
дель.
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Introduction
Hyperlipidemia is a well-established risk factor 
for developing cardiovascular disease (CVD)[1]. Mul-
tiple double blind placebo controlled trials have shown 
that treatment with HMG CoA Reductase inhibitors 
(statins) lowers low-density lipoprotein (LDL)-C lev-
els and reduces CVD events in individuals with CVD 
or those at high risk for developing it [2, 3]. However, 
CVD events continue to occur in some patients on sta-
tins, despite receiving maximal tolerated therapy. Other 
patients develop side effects from statins that limit their 
use. Hence, newer modalities of treatment to lower 
LDL-C are needed in clinical practice. Recently the 
Food and Drug Administration (FDA) approved two 
medications which target a novel pathway to reduce 
LDL-C. They are monoclonal antibodies that inactivate 
proprotein convertasesubtilsin-kexin type 9 (PCSK9) 
[4]. The 1985 Nobel Prize for Physiology or Medicine 
was awarded to Michael Brown and Joseph Goldstein 
for their research into the link between cholesterol me-
tabolism and coronary artery disease. This research 
increased our understanding of the pathophysiology 
of disorders such as familial hypercholesterolaemia, 
and paved the way for important therapies like statins 
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Fig. 1.  Time-line of developments in the history of PCSK9.
(HMG-CoA reductase inhibitors). They found that the 
low-density lipoprotein (LDL) receptor, expressed pri-
marily in the liver, was responsible for clearing LDL 
particles from plasma. Statins decrease the intracellular 
concentration of cholesterol in the liver. This increases 
the expression of LDL receptors and more LDL choles-
terol is removed from the circulation [5].
PCSK9 (proprotein convertase subtilisin/kexin 
type 9) was first described in 2003 (Figure 2). Hepa-
tocytes are the predominant site for PCSK9 produc-
tion, with other sites being intestines and kidneys [4]. 
PCSK9 reduces the number of LDLR in hepatocytes 
by promoting their metabolism and subsequent degra-
dation [14]. PCSK9 has been shown to act both intra-
cellulary (playing a role as a chaperone) as well as a se-
creted factor promoting LDLR internalization from the 
hepatocellular surface. Under normal circumstances, 
the LDL/LDLR complex is endocytosed by endoso-
mes.  In its active form, PCSK9 regulates cell surface 
receptors, in particular the LDL receptor. The enzyme 
encoded by the PCSK9 gene is primarily expressed in 
the liver [5].
PCSK9 inhibitory antibodies. Studies of un-
common mutations, such as the LDL-receptor muta-
tions in familial hypercholesterolaemia, have led to 
important therapeutic advances in the study of lipids 
and cardiovascular disease. Proprotein convertase sub-
tilisin/kexin type 9 (PCSK9) is an enzyme involved in 
the regulation of LDL receptors and LDL cholesterol. 
By tagging LDL receptors for destruction in the liver, 
PCSK9 increases concentrations of LDL cholesterol 
[6]. Plasma PCSK9 concentrations are raised by sta-
tins and this could attenuate the effect of these drugs. 
Research has focused on PCSK9 as a therapeutic target 
because blocking its action could reduce LDL choles-
terol. The first candidates for therapies were humanised 
monoclonal antibodies.  Alirocumab, evolocumab and 
bococizumab are in commercial development. These 
are all given by subcutaneous injection and reach a 
maximal effect 5 – 7 days after the dose, which lasts 
for about two weeks.Phase I trials started in 2012, and 
showed large reductions in LDL cholesterol. The anti-
bodies were well tolerated, including in patients intol-
erant of statins. In addition to the effect on LDL cho-
lesterol, PCSK9 inhibition also reduces lipoprotein(a) 
and has favourable effects on other lipoproteins such 
as triglycerides, HDL and Apo B [7]. Lipoprotein(a) is 
a recognised risk factor for atherosclerotic disease and, 
to date, has not been shown to respond to any conven-
tional therapies.
Clinical studies. One of the first studies of PCSK9 
antibody therapies was the RUTHERFORD study. 
This involved 167 very high-risk patients with hete-
rozygous familial hypercholesterolaemia, treated with 
evolocumab every four weeks for 12 weeks. These 
patients were on stable lipid-lowering treatment with 
a statin with or without ezetemibe. The highest dose 
of evolocumab resulted in a drop in LDL cholesterol 
from 3,8 to 1,7 mmol/L (55%, p<0.001 vs placebo) [7]. 
The phase II OSLER-1 and phase III OSLER-2 studies 
were two open-label trials of evolocumab in combina-
tion with standard therapy. They involved more than 
4000 patients for a median of 11,1 months. In patients 
treated with evolocumab, there was a fall in median 
LDL-cholesterol concentration from 3,1 mmol/L to 
1,24 mmol/L (61%) with little change seen in the con-
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trol group. Although the study design only allowed 
cardiovascular events to be analysed as an exploratory 
analysis, the event rate was 0,95% in the study group, 
compared with 2,18% in the control group (relative 
risk reduction 56%, p=0,003) [8]. The ODYSSEY 
phase III double-blind trial of alirocumab versus pla-
cebo involved 2341 patients at very high risk. Follow-
ing injections every two weeks there was lowering of 
LDL cholesterol after 24 weeks. Major cardiovascular 
events were lower in the alirocumab group compared 
with controls (1,7% vs 3.3%, p=0,02). Lipoprotein(a) 
was also observed to fall by 26% [9]. Evolocumab is 
a human monoclonal antibody that inhibits proprotein 
convertase subtilisin/kexin type 9 (PCSK9). Repatha 
binds to PCSK9 and inhibits circulating PCSK9 from 
binding to the low-density lipoprotein (LDL) receptor 
(LDLR), preventing PCSK9-mediated LDLR degrada-
tion and permitting LDLR to recycle back to the liver 
cell surface. By inhibiting the binding of PCSK9 to 
LDLR, Repatha increases the number of LDLRs avail-
able to clear LDL from the blood, thereby lowering 
LDL-C levels [21]. Repatha Cardiovascular Outcomes 
(FOURIER) Study: Key Outcomes. The 27,564-patient 
Evolocumab cardiovascular outcomes study (FOU-
RIER) demonstrated that adding Evolocumab to opti-
mized statin therapy resulted in a statistically signifi-
cant 20 percent (p<0,001) reduction in major adverse 
cardiovascular events (MACE) represented in the key 
secondary composite endpoint of time to first heart at-
tack, stroke or cardiovascular death. The study found a 
statistically significant 15 percent reduction (p<0,001) 
in the risk of the primary composite endpoint, which 
included hospitalization for unstable angina, coronary 
revascularization, heart attack, stroke or cardiovascu-
lar death. The magnitude of risk reduction in both the 
primary and key secondary composite endpoints grew 
over time, with the robust benefit starting as early as 
six months and accruing through the median 2.2 years 
of the study. Patients on Evolocumab experienced a re-
duction in the risk of heart attack (27 percent, nominal 
p<0,001), stroke (21 percent, nominal p=0,01) and cor-
onary revascularization (22 percent, nominal p<0,001)
in patients treated with evolocumab and statin therapy 
compared to patients treated with placebo and statin 
therapy over a mean duration of 26 months. There was 
no observed effect on hospitalizations for unstable an-
gina.  Consistent with recent trials of more intensive 
LDL-C lowering, there was no significant effect on car-
diovascular mortality [17-20].
Therapeutic use. To date, studies of anti-PCSK9 
antibodies have examined the lowering of LDL choles-
terol, with cardiovascular outcomes being analysed post 
hoc based on a relatively small number of events. Ali-
rocumab and Evolocumab have recently been approved 
by the Food and Drug Administration (FDA). Much 
larger trials are in progress, which should determine 
cardiovascular outcomes and less common adverse ef-
fects. The FOURIER study of evolocumab involves 27 
500 high-risk patients with cardiovascular disease on 
background statin therapy. Similar trials of alirocumab 
and bococizumab are in progress.Alirocumab was ap-
proved by the Food and Drug Administration in July 
2015 for use in addition to diet and maximally toler-
ated statin therapy in adult patients with heterozygous 
familial hypercholesterolaemia or patients with clinical 
atherosclerotic cardiovascular disease. Alirocumab is 
available as a 75 mg/mL pre-filled pen or syringe and 
is given every two weeks by subcutaneous injection at 
a dose of 75–150 mg [10]. Shortly afterwards, evolo-
cumab was approved for a similar group of patients. 
The recommended dose is 140 mg two-weekly or 420 
mg once monthly. Evolocumab is available in a 140 
mg/mL singleuse prefilled syringe or autoinjector [11]. 
The monthly dose of evolocumab is more than double 
the dose of two-weekly injections because the drug has 
non-linear pharmacokinetics. Its plasma concentrations 
do not increase in proportion to the administered dose 
[12]. Evolocumab was also approved in August, 2015 
for use in adult patients with heterozygous familial 
hypercholesterolemia, homozygous familial hypercho-
lesterolemia, or clinical atherosclerotic CVD requiring 
additional lowering of LDL cholesterol after being on a 
controlled diet and maximally-tolerated statin therapy 
[12, 13]. These new drugs for lowering LDL choles-
terol may become a valuable addition to, or a substitute 
for, current lipid-lowering therapies. Until the results 
from large phase III trials are able to clearly delineate 
harms and benefits, their role is likely to be restricted 
to patients with a high cardiovascular risk who do not 
reach targets for LDL cholesterol with oral therapy.
These trials may also uncover rare adverse effects. The 
need for subcutaneous injection may also make pa-
tients reluctant to use the antibodies, and some patients 
may need to have their doses administered by health 
professionals [14].
THOUSAND OAKS, Calif., May 16, 2018 /
PRNewswire/ – Amgen (NASDAQ:AMGN)  an-
nounced that the European Commission (EC) has ap-
proved a new indication in the evolocumab label for 
adults with established atherosclerotic cardiovascular 
disease (myocardial infarction, stroke or peripheral 
arterial disease) to reduce cardiovascular risk by low-
ering low-density lipoprotein cholesterol (LDL-C) lev-
els. With the expanded label now in place, Amgen is 
working with payers in Europe to remove prescribing 
barriers and expand access in order to reach patients 
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with established cardiovascular disease who are at risk 
of another event [15].
Adverse effects. Arthralgia, headache, limb pain 
and fatigue were more frequent in the OSLER stud-
ies of evolocumab than in controls, but liver function 
and creatine kinase were unchanged. Injection site re-
actions led to six patients (0,2%) stopping treatment. 
Neurocognitive changes were more common with 
evolocumab, but were infrequent (0,9%, compared 
with 0.3% in the placebo group) and were not related 
to the concentration of LDL cholesterol. A dedicated 
neurocognitive substudy of evolocumab is under way 
to give a more definitive assessment. The occurrence 
of adverse effects may have been confounded by the 
open-label method of the study, as patients treated with 
evolocumab were examined more frequently than con-
trols. Evolocumab-binding antibodies were found in 
0,3% of treatment and control patients, and were tran-
sient on repeat testing. No neutralising antibodies were 
observed.In the ODYSSEY trial overall adverse event 
rates were similar in the alirocumab and placebo groups. 
Discontinuation due to adverse events was 7,2% in the 
alirocumab group and 5,8% in the control group. My-
algia was more frequent with alirocumab than with pla-
cebo (5,4% vs 2,9%, p=0,006). Other adverse events 
included injection site reactions, neurocognitive events 
related mainly to memory, ophthalmologic events, and 
changes in transaminase and creatine kinase concentra-
tions. The rate of diabetes development was not signifi-
cantly different between groups [9, 16].
Conclusion
PCSK9 inhibitory antibody therapies target a 
novel pathway in LDL-cholesterol metabolism, and 
early phase I and II trials show highly promising re-
sult. The story of PCSK9 since its discovery just over 
a decade ago is an important case study in translating 
research into practice. PCSK9-inhibiting therapies 
have efficacy in lowering LDL cholesterol which could 
decrease the risk of atherosclerotic cardiovascular dis-
ease, particularly in high-risk patients. They could re-
duce the need for radical therapies such as lipoprotein 
apheresis in patients with severe heterozygous famil-
ial hypercholesterolaemia, and homozygous familial 
hyper cholesterolaemia with residual LDL-receptor 
function.
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